BT_RT 1.19 - Malignant Hyperthermia Flashcards
(71 cards)
MH summary
An inherited multifactorial channelopathy marked by uncontrolled release of calcium ions (Ca2+) from the sarcoplasmic reticulum of skeletal muscle in response to halogenated volatile agents and succinylcholine
Potentially lethal
Pathophysiology (acute progression of the disease): clinical features —> terminal stage
Most obvious manifestation is pharmalogically triggered massive and persistent increase in cytoplasmic calcium ion concentration. Results in metabolic stimulation and sustained contractile activity with disruption of sarcolemmal integrity
Clinical features
First signs usually tahycardia and a ↑PaCO2
increased O2 consumption
CO2 production –> ↑PaCO2
Arrythmias
Hyperthermia (↑2℃/hour)
Acidosis
Rhabdomyolysis
muscle rigidity
Progresses to
Extreme acidosis as a result of acute loss of control of intracellular ionized Ca. Specifically, a mixed metabolic and respiratory acidosis
↑ metabolism –> ↑ CO2 production
Byproducts of anaerobic respiration e.g. lactate contribute to metabolic acidosis
Can proceed to severe rhabdomyolysis
Myoglobinuria, ARF
Terminal stage
Mitochondrial failure brought due to mitochondrial Ca accumulation is a critical point
Death results from:
hyperkalaemia,
DIC (secondary to hyperthermia),
profound acidosis,
hyperthermia
Epidemiology
Incidence 1:15,000 GAs in kids, 1:50,000 GAs in adults
MH is more common in children and young adults compared to adults due to the higher incidence of exposure to triggering anaesthetic agents during surgical procedures
Triggers and protective factors
Volatile anaesthetics
Act on RyR1 by overriding the physiologic magnesium inhibition of the channel
Effect may be immediate or delayed up to 6 hours - worsens with ongoing dosing
Suxamethonium
Only a weak trigger (H&E) of hypermetabolic response at worst when administered without volatiles, although some sources say it is a potent trigger
With volatiles, it will cause generalised or jaw muscle rigidity and enhance the onset and severity of the reaction triggered
Anecdotally, when triggered by the more modern volatile agents (sevoflurane, desflurane), the presentation is less fulminant compared to the older triggers (halothane, suxamethonium)
Normal functioning of calcium release in the myocyte
Tightly regulated bidirectional interaction between the voltage sensor of the T-tubular sarcolemmal membrane (dihydropyridine receptor [DHPR]) the calcium release channel of the sarcoplasmic reticulum (ryanodine receptor isoform 1 [RyR1])
Activated by Ca at lower concentrations
Inhibited at high concentrations of Ca
Mg-induced inhibition is the second important regulator
Mg acts by competing with Ca at its activator sites and by binding to yet unidentified low-affinity inhibitory sites
Mg2+ exerts a regulatory role on RyR1, inhibiting the opening of the receptor channel at rest.
As an AP arrives down T-tubule the Dihydropyridine receptor acts as a voltage sensor with the change in membrane potential causing a conformational change in the dihydropyridine receptor, which interacts with RyR1 to overcome the inhibitory effect of Mg2+, thus allowing Ca2+ release
Steps of management
Immediate
ABCs
Dantrolene
Treat complications
Ongoing management
Management
Immediate
Declare MH emergency ·
Call for help, need many hands
Stop the offending agent(s) ASAP
Cease volatile if using, FGF >10L/min to flush circuit, ↑FiO2 to 100%
Start IV sedation e.g. propofol 300mg/h
Surgical management
Stop surgery if possible
Else call senior surgeon to complete surgery rapidly
Management
ABCs
intubate if airway not already secured, do not use suxamethonium
Hyperventilate with FiO2 100%, high flow 15L/min to flush out residual volatile agent, and to lower the ↑ PaCO2
ensure BP within safe limits, insert arterial line
sedate e.g.propofol 200mg/h
Management
Dantrolene dose
Bolus dose: 2.5mg/kg rapidly ± repeat; may require >10mg/kg
Infusion for up to 24h: 1mg/kg/h
Management
Treat complications
Hyperkalemia
Hyperventilation
Calcium
Salbutamol
Insulin, glucose
Acidosis management
Hyperventilation
NaHCO3
Arrhythmia management
Amiodarone
Lignocaine
Renal protection
Maintain UO >2ml/kg/hr
Maintain intravascular volume
Mannitol in dantrolene formulation
Haemodynamic management
Vasopressor/Inotropic support as needed
Hyperthermia management –> Cool to 37C
Ice packing to exposed areas
Cold IV saline lavage
Cold bladder or intraperitoneal irrigation
Reduce OT thermostat to lowest setting
Supportive management and investigations
Arterial line
Central line
Check for DIC, CK, myoglobinuria
Management
Ongoing
ICU
Dantrolene 1mg/kg q6hr for 24–48hr
Maintain renal protective strategies
Susceptibility testing
At a later time, pt and relatives can be tested for MH with muscle biopsy, using caffeine-halothane contracture testing or genetic testing
Medialert bracelet
Dantrolene
Uses
Used in the treatment of:
malignant hyperthermia
neuroleptic malignant syndrome
heat stroke, and
muscle spasticity and may be of use
as an adjunct in the treatment of tetanus.
Dantrolene
Chemical + Presentation
Phenyl hydantoin derivative
Presentation
Old formulation (Dantrium)
Light yellow, lyophilised powder of dantrolene 20mg
Mannitol 3g (will cause diuresis)
NaOH
Each 20mg vial should be reconstituted in 60ml sterile water → pH 9.5
Very slow to mix, needs to be shaken vigorously
New formulation (Ryanodex)
Dantrolene 250mg vials
Mannitol 0.125g
Reconstitute in 5ml sterile water → pH 10.3
Easier to mix
As 25 or 100 mg capsules of dantrolene sodium
Dantrolene
Main action and mode of relaxation
Main Action
Muscular relaxation.
Mode of action
Reduces sarcoplasmic Ca concentration below contractile threshold - mechanism not fully elucidated
Binds to ryanodine receptor and interferes with calcium release from sarcoplasmic reticulum → uncoupling of excitation-contraction
Action via inhibition of RyR1 receptors in SR
Appears to be dependent on elevated sarcoplasmic Mg concentration
Also attenuates depolarized-triggered Ca entry
pathologic release of Ca2+ from the SR that leads to muscle contraction, generation of heat, lactate and CO2, release of Ca2+ is central to glycogen metabolism , mitochondrial respiratory function and contraction of actin – myosin filaments.
Results in reduced muscular contraction to a given electrical stimulus
Part of its action may be due to a marked GABA-ergic effect.
Dantrolene
Routes of administration + doses
1-10 mg/kg as required (2 mg/kg doses repeated every 5 mins) via fast running infusion
The average dose required is 2.5 mg/kg
A 70kg patient might need 700mg = 35 vials
In ICU, 1mg/kg q6hr for 24–48hr
oral adult dose used for the prevention of spasticity is 25–100 mg 6-hourly
Dantrolene
Onset + duration
Onset time
therapeutic effect in 15 minutes
Duration
lasts 4-6 hours
Dantrolene
Effects
No effect on cardiac or CNS ryanodine receptor
skeletal muscle relaxation, resp paralysis
marked central GABA-ergic effects; sedation may occur.
Improves B adrenergic responsiveness in failing myocardium
increases the effectiveness of voiding in many patients with neuromuscular disorders
cannot cause complete paralysis
Dantrolene
Toxicity/side effects
Highly irritant if extravasates due to alkaline pH 9.5 - can cause necrosis
Reversible hepatic dysfunction in 2%, rarely may cause fatal hepatic failure
Chronic use may lead to muscular weakness
Hyperkalaemia with VF if given concurrently with verapamil
Marked GABAergic effect may cause sedation
The diluent volume required to administer large doses of dantrolene may precipitate acute pulmonary oedema.
Potentiates the skeletal muscle relaxation of non-depolarising muscle relaxants.
Fade
Description
Progressive reduction in twitch height with high frequency stimulation (e.g. TOF)
Occurs in non-depolarizing drugs only
Fade
Use
Measurement of fade via train-of-four stimulation (TOF): 4x supramaximal stimuli, each lasting 0.2 msec, delivered at frequency of 2Hz –> measure number and height of twitches Height of fourth relative to first twitch (T4:T1) = train-of-four ratio –> reflects fade
Degree of fade correlates with depth of blockade
Fade
Mechanism
Blockade of pre-synaptic α3β2 nAChR
Loss of positive feedback associated with repeated stimuli
Inability to mobilise reserve pool of ACh
Why do you not get fade with a depolarising blockade?
Only not seen during the phase 1 blockade, presumably because the SCh does not act on the presynaptic receptors at that point